Posted October 25, 2018 07:06:22The new Bayer, the world’s biggest pharmaceutical company, has been in a frenzy.

With the acquisition of Boehninger Ingels, Bayer has made an effort to diversify its portfolio and, as a result, it is now offering two new drugs for people who suffer from asthma.

One of the drugs, Asthma Treatment Plus, is being marketed as a first line drug for people with asthma.

The company says that the drug can be taken daily and it works by boosting lung function, breathing and other vital signs.

The other drug, AstraZeneca, is also a first-line drug and is being offered in a limited number of doses for people suffering from asthma, but with a smaller dose.

The drug is being developed by Astra Zeneca’s sister company, Astellas Therapeutics.

The Bayer-Pfizer deal is the latest development in a string of deals between the two companies, and it could have ramifications for the rest of the pharmaceutical industry.

The Pfizer deal will have an impact on both the number of medications available to the public, as well as on pricing.

For now, Asta has the best pricing in the industry.

But, if Astra has a longer lead in clinical trials, then it will be important for Astra to have better pricing to compensate for the lower prices.

In the coming months, it will become more difficult for Asta to sell more drugs, as Astra also faces competition from Astra’s other two drug lines, Astrolab and Pfogenz.

In addition, the Pfizer-Bayer deal will likely affect Astra, too.

Pfizer is currently a leader in Astra-related research and development, and Astra is currently an early-stage investor in Asta-related companies.

The deal also gives Pfizer access to the largest and most powerful market in the world.

In a statement, Bayer said that it was confident that Astra would be able to make the right financial decisions for Pfizer.

In addition, Astas management team is fully committed to working closely with Pfizer, Bayer and Asta on Astra product development and development plans.

Bayer’s Astra subsidiary is one of the most successful in the pharmaceutical sector, with a total of more than 1,000 different products and a market cap of more,5 billion euros.

In 2017, the company acquired the patent for the Astra drug AstraA, and in 2018, it acquired a patent for Astha treatment for asthma.

As of October 25 the Bayer-Boehringers combined market value was more than 5 billion euros, and its stock value is currently trading at a high of over 1.6 billion euros (1.6 times earnings).

The Pfizer acquisition will likely impact Astra as it is already a major player in the Asta market, but it could also have significant implications for the other major players in the asthma market.

Astra Pharmaceuticals is the third-largest brand in the entire Astra category, and Pfizers own Astra brand is currently the top-selling Astra medication.

According to Bloomberg, the Astana deal has raised concerns in the medical community about Astra Pharma’s continued growth and its potential impact on the industry overall.

Asta, a unit of Astra Therapeutic, had a market value of about 3.6 trillion euros in 2017, and by 2018, the value of Asta Pharma had surpassed the value that Pfizer holds.

It’s unclear how the Asthma Industry Alliance, the trade group representing the industry, will respond to the Bayer/Pfinity deal.